The pharmaceutical manufacturing industry will see strong profit growth in 2021, with a year-on-year increase of nearly 80%

According to data released by the National Bureau of Statistics recently, in 2021, the total profits of industrial enterprises above designated size in the country will be 8,709.
21 billion yuan, an increase of 34.
3% over the previous year (calculated on a comparable basis)
.
Among the 41 major industrial sectors, 32 of them have increased profits over the previous year, accounting for 78.
0%
.
Among them, the pharmaceutical manufacturing industry will see strong profit growth in 2021, with a year-on-year increase of nearly 80%
.
Pharmaceutical manufacturing industry (Source: Pharmaceutical Network) The profit of the pharmaceutical manufacturing industry in 2021 will increase by 77.
9% year-on-year.
Among the 32 industries whose profits have increased over the previous year, the pharmaceutical manufacturing industry has seen a strong growth in profits, with a total profit of 627.
14 billion yuan in 2021, a year-on-year increase.
an increase of 77.
9%
.
Data from January to November 2021 shows that the total profits of industrial enterprises above designated size in the country are 7,975.
01 billion yuan, a year-on-year increase of 38.
0%
.
Among them, the pharmaceutical manufacturing industry realized a total profit of 540.
35 billion yuan, a year-on-year increase of 70.
8%
.
It can be seen that in December 2021, the profit of the pharmaceutical manufacturing industry maintained a trend of rapid growth
.
According to the previous interpretation of the profit data of industrial enterprises in the third quarter of 2021 by the National Bureau of Statistics, the pharmaceutical manufacturing industry is mainly driven by factors such as the large demand for domestic and foreign vaccines and the booming production and sales of enterprises.
The profit in the third quarter increased by 66.
8% year-on-year, continuing in early 2021.
rapid growth since
.
The large demand for vaccines in the pharmaceutical manufacturing industry and the prosperous production and sales of enterprises can be reflected in the annual reports of major enterprises
.
As of February 24, more than 20 pharmaceutical companies have released performance reports, including Zhifei Bio, Tiantan Bio, Wantai Bio, Chengda Bio, and Baike Bio
.
Among them, more than half of the companies reported good performance
.
The profitability of some vaccine companies will increase significantly in 2021
.
For example, Wantai Bio will realize revenue of 5.
750 billion yuan in 2021, a year-on-year increase of 144.
25%; net profit of 2.
016 billion yuan, a year-on-year increase of 197.
83%
.
The company said that the main reason for the change in performance was the increase in net profit brought about by the increase in revenue from bivalent cervical cancer vaccines, reagents and active raw materials
.
Another example is Zhifei Biology.
In 2021, the company's revenue is 30.
637 billion yuan, a year-on-year increase of over 100%; the total profit is 10.
197 billion yuan, a year-on-year increase of 208.
88%
.
The company mentioned in the 2021 performance report that during the reporting period, the sales of the company's own products and agency products continued to increase steadily, and the company's main business income, net profit and other important financial indicators increased significantly compared with the same period of the previous year
.
Zhifei Bio is a company engaged in the research, development, production and sales of vaccines and biological products
.
According to the company's 2021 interim report, the company has 10 products on the market, 1 product for emergency use, including vaccine products to prevent infectious diseases such as meningitis, cervical cancer, pneumonia, and rotavirus, as well as providing diagnosis of tuberculosis infection , prevention and treatment of effective solutions, covering groups including infants, adolescents and adults
.
Operating costs increased by 12.
7% year-on-year In 2021, the operating income of the pharmaceutical manufacturing industry will be 2,928.
85 billion yuan, a year-on-year increase of 20.
1%
.
It is worth mentioning that the operating cost of the pharmaceutical manufacturing industry in 2021 will also increase by 12.
7% year-on-year
.
According to the notes, the so-called operating costs refer to the actual costs incurred by an enterprise engaged in production and business activities such as selling commodities, providing labor services and transferring the right to use assets
.
Including main business costs and other business costs
.
Operating costs should be matched with operating income
.
Generally speaking, the reasons for the increase in the operating cost of enterprises mainly include the increase in material prices, the increase in labor costs, and the increase in manufacturing costs
.
In recent years, rising raw material prices and rising labor costs have become evident in the pharmaceutical manufacturing industry
.
From the annual data, it can be seen that there are still certain challenges in cost management for pharmaceutical manufacturing enterprises in the future
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.